Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer PatientsAccesswire • 07/14/21
Blazing Biotechs Highlight Stocks Trading Under $10 With Massive Upside Potential24/7 Wall Street • 07/10/21
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to VoteAccesswire • 07/09/21
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to VoteAccesswire • 06/11/21
REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM EasternAccesswire • 06/02/21
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EUAccesswire • 06/01/21
Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPACAccesswire • 06/01/21
Napo Pharmaceuticals, Jaguar Health's Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical OfficerAccesswire • 05/26/21